Profile data is unavailable for this security.
About the company
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
- Revenue in INR (TTM)17.58bn
- Net income in INR4.78bn
- Incorporated1990
- Employees859.00
- LocationCaplin Point Laboratories LtdNarbaviNo. 3, Lakshmanan Street,, T. Nagar,CHENNAI 600096IndiaIND
- Phone+91 4 428156653
- Fax+91 4 428154952
- Websitehttps://www.caplinpoint.net/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 84.75bn | 931.00 | 173.50 | -- | 55.37 | 7.16 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 86.14bn | 1.41k | 42.88 | 16.00 | 37.72 | 7.48 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 90.40bn | 447.00 | 57.42 | -- | 49.42 | 13.01 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| F D C Ltd | 20.45bn | 3.14bn | 91.82bn | 6.66k | 29.35 | -- | 25.82 | 4.49 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Strides Pharma Science Ltd | 42.09bn | -475.19m | 118.30bn | 3.07k | -- | -- | 85.63 | 2.81 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Granules India Ltd | 47.01bn | 4.92bn | 130.85bn | 4.12k | 26.61 | -- | 18.61 | 2.78 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 134.06bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 141.13bn | 2.01k | 31.64 | -- | 28.11 | 6.15 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 144.26bn | 2.00k | 43.18 | -- | 34.80 | 6.36 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 147.43bn | 859.00 | 30.95 | -- | 27.30 | 8.39 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Wockhardt Ltd | 28.93bn | -3.43bn | 158.40bn | 2.39k | -- | -- | -- | 5.48 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 163.85bn | 1.65k | 48.76 | -- | 41.12 | 10.02 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 166.05bn | 2.17k | 38.64 | 24.26 | 35.48 | 6.97 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 171.82bn | 940.00 | 179.24 | -- | 154.92 | 12.38 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Eris Lifesciences Ltd | 22.62bn | 3.80bn | 185.98bn | 3.08k | 48.96 | -- | 30.47 | 8.22 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 190.99bn | 995.00 | 34.59 | -- | 20.51 | 2.79 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Data as of Sep 20 2024. Currency figures normalised to Caplin Point Laboratories Ltd's reporting currency: Indian Rupee INR
3.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Aug 2024 | 1.11m | 1.47% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 436.27k | 0.57% |
| Principal Global Investors LLCas of 31 Jul 2024 | 210.24k | 0.28% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 148.15k | 0.20% |
| Mellon Investments Corp.as of 05 Sep 2024 | 147.18k | 0.19% |
| PineBridge Investments Asia Ltd.as of 31 Dec 2023 | 87.75k | 0.12% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 48.69k | 0.06% |
| BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 41.57k | 0.06% |
| The Vanguard Group, Inc.as of 31 Jul 2024 | 35.67k | 0.05% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Aug 2024 | 18.92k | 0.03% |
More ▼
Data from 30 Jun 2024 - 19 Sep 2024Source: FactSet Research Systems Inc.
